Level and clinical significance of serum CXC chemokine ligand 13 in patients with hepatocellular carcinoma.

IF 1.5 4区医学 Q4 ONCOLOGY

Translational cancer research Pub Date : 2025-01-31 Epub Date: 2025-01-23 DOI:10.21037/tcr-24-1306

Ye-Ting Wu, Xiao-Juan Ran, Qi-Zhe Li, Yi-Qi Wu, Xiao-Xu Shen, Mao Mu, Quan Zhang

{"title":"Level and clinical significance of serum CXC chemokine ligand 13 in patients with hepatocellular carcinoma.","authors":"Ye-Ting Wu, Xiao-Juan Ran, Qi-Zhe Li, Yi-Qi Wu, Xiao-Xu Shen, Mao Mu, Quan Zhang","doi":"10.21037/tcr-24-1306","DOIUrl":null,"url":null,"abstract":"Background: CXC chemokine ligand 13 (CXCL13) serves as the ligand for chemokine receptor 5 (CXCR5), The CXCL13/CXCR5 signaling axis plays a crucial role in the pathogenesis and progression of various malignancies. This study aimed to assess the expression and role of serum CXCL13 in patients with hepatocellular carcinoma (HCC) and explore its clinical significance in the diagnosis, treatment, and prognosis evaluation of HCC.Methods: Serum samples and clinical data were collected from 74 HCC patients, 51 cirrhosis patients, and 53 healthy controls. The expression level of serum CXCL13 was measured using enzyme-linked immunosorbent assay (ELISA). Statistical software was employed to analyze the relationship between CXCL13 levels and clinicopathological features as well as laboratory indicators. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of CXCL13 and alpha-fetoprotein (AFP) for HCC.Results: The level of serum CXCL13 in the HCC group (275.96±145.35 pg/mL) was significantly higher than that in the cirrhosis group (172.11±142.78 pg/mL) and healthy control group (58.83±41.29 pg/mL). The level of CXCL13 in HCC patients with tumor node metastasis (TNM) stage III-IV was significantly higher than that in those with TNM stage I-II, as well as positively correlated with γ-glutamyltransferase (GGT) and model for end-stage liver disease (MELD) values. The area under the ROC curve for CXCL13, AFP, and the combination of CXCL13 with AFP were 0.819, 0.813, and 0.885 respectively. The sensitivity and specificity of the combined CXCL13 with AFP were 88.9% and 77.9% respectively. Moreover, the diagnostic efficacy of combining CXCL13 with AFP was significantly superior to that of using either CXCL13 or AFP alone.Conclusions: The expression of CXCL13 is upregulated in HCC patients and associated with tumor size, metastasis, GGT, and MELD score. Combining serum CXCL13 with AFP may hold clinical value to the diagnosis of HCC.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"424-433"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833404/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1306","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: CXC chemokine ligand 13 (CXCL13) serves as the ligand for chemokine receptor 5 (CXCR5), The CXCL13/CXCR5 signaling axis plays a crucial role in the pathogenesis and progression of various malignancies. This study aimed to assess the expression and role of serum CXCL13 in patients with hepatocellular carcinoma (HCC) and explore its clinical significance in the diagnosis, treatment, and prognosis evaluation of HCC.

Methods: Serum samples and clinical data were collected from 74 HCC patients, 51 cirrhosis patients, and 53 healthy controls. The expression level of serum CXCL13 was measured using enzyme-linked immunosorbent assay (ELISA). Statistical software was employed to analyze the relationship between CXCL13 levels and clinicopathological features as well as laboratory indicators. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of CXCL13 and alpha-fetoprotein (AFP) for HCC.

Results: The level of serum CXCL13 in the HCC group (275.96±145.35 pg/mL) was significantly higher than that in the cirrhosis group (172.11±142.78 pg/mL) and healthy control group (58.83±41.29 pg/mL). The level of CXCL13 in HCC patients with tumor node metastasis (TNM) stage III-IV was significantly higher than that in those with TNM stage I-II, as well as positively correlated with γ-glutamyltransferase (GGT) and model for end-stage liver disease (MELD) values. The area under the ROC curve for CXCL13, AFP, and the combination of CXCL13 with AFP were 0.819, 0.813, and 0.885 respectively. The sensitivity and specificity of the combined CXCL13 with AFP were 88.9% and 77.9% respectively. Moreover, the diagnostic efficacy of combining CXCL13 with AFP was significantly superior to that of using either CXCL13 or AFP alone.

Conclusions: The expression of CXCL13 is upregulated in HCC patients and associated with tumor size, metastasis, GGT, and MELD score. Combining serum CXCL13 with AFP may hold clinical value to the diagnosis of HCC.

查看原文本刊更多论文

肝癌患者血清CXC趋化因子配体13水平及临床意义

背景：CXC趋化因子配体13 （CXCL13）作为趋化因子受体5 （CXCR5）的配体，CXCL13/CXCR5信号轴在多种恶性肿瘤的发病和进展中起着至关重要的作用。本研究旨在评估血清CXCL13在肝细胞癌（HCC）患者中的表达及作用，探讨其在HCC诊断、治疗及预后评价中的临床意义。方法：收集74例HCC患者、51例肝硬化患者和53例健康对照者的血清和临床资料。采用酶联免疫吸附法（ELISA）检测血清CXCL13的表达水平。采用统计学软件分析CXCL13水平与临床病理特征及实验室指标的关系。采用受试者工作特征（ROC）曲线分析，评价CXCL13和甲胎蛋白（AFP）对HCC的诊断价值。结果：HCC组血清CXCL13水平（275.96±145.35 pg/mL）明显高于肝硬化组（172.11±142.78 pg/mL）和健康对照组（58.83±41.29 pg/mL）。HCC肿瘤淋巴结转移（TNM） III-IV期患者CXCL13水平显著高于TNM I-II期患者，且与γ-谷氨酰转移酶（GGT）和终末期肝病模型（MELD）值呈正相关。CXCL13、AFP及CXCL13联合AFP的ROC曲线下面积分别为0.819、0.813、0.885。CXCL13联合AFP的敏感性和特异性分别为88.9%和77.9%。此外，CXCL13联合AFP的诊断效果明显优于单独使用CXCL13或AFP。结论：CXCL13在HCC患者中表达上调，并与肿瘤大小、转移、GGT和MELD评分相关。结合血清CXCL13与AFP对HCC的诊断有一定的临床价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.